阿托伐他汀对原发性高血压患者血压及内源性纤溶活性的影响

目的　通过对阿托伐他汀调脂同时对原发性高血压 (EH)患者血压及内源性纤溶活性影响的观察 ,探讨其非调脂作用。方法　观察 4 2例 1级原发性高血压患者 ,口服阿托伐他汀 10mg ,2 /d ,8周 ,分别对患者治疗前及治疗后进行血压、血清总胆固醇 (TC)、甘油三酯 (TG)、低密度脂蛋白胆固醇 (LDL -C)、高密度脂蛋白胆固醇 (HDL -C)、分泌组织性纤溶酶原激活因子 (t-PA)和纤溶酶原激活抑制因子 (PAI - 1)检测。结果　与正常对照组比较 ,EH组治疗 8周后收缩压均有显著降低 (P <0 .0 5 ) ,t-PA活性明显升高 (P <0 .0 1) ,PAI - 1活性明显降低 (P <0 .0 5 ) ,EH并血脂紊乱 (EHA)组治疗后TC、TG、LDL -C较治疗前均显著降低 (P <0 .0 1) ,HDL -C明显升高 (P <0 .0 5 )。结论　阿托伐他汀在有效调脂同时可发挥其非调脂作用 ,能降低EH患者血压及改善内源性纤溶活性

EFFECT OF ATORVASTATIN ON BLOOD PRESSURE AND ENDOGENOUS TISSUE TYPE PLASMINOGEN ACTIVATOR IN PATIENTS WITH ESSENTIAL HYPERTENSION

Objective To approach the nonlipid-lowering function of Atorvastatin by observing the effect of Atorvastation on blood pressure and endogenous tissue type plasminogen activator in patients with essential hypertension. Methods Blood pressure(BP), total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C), tissue type plasminogen activator(t-PA), tissue type plasminogen active inhibitor(PAI-1) were measured in 28 normotensive subjects as control group and 42 patients with class 1 essential hypertension before and 8 weeks after drug administration. Results Plasma levels of BP after drug administration in 42 patients were significantly decreased than those in control group(P<0.05),and the levels of TC,TG,LDL-C, t-PA activator were significantly increased in 42 patients. Conclusion Atrorvastatin could decrease BP and improve endogenous tissue type plasminogen activator,takes the lipid adjusting and nonlipid-lowering function at the same time.